These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2232 related articles for article (PubMed ID: 18775388)

  • 1. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
    Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
    Akazawa M; Hayflinger DC; Stanford RH; Blanchette CM
    Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.
    Dalal AA; Shah M; D'Souza AO; Crater GD
    Respir Med; 2012 Jun; 106(6):829-37. PubMed ID: 22425138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
    Dalal AA; Candrilli SD; Davis KL
    Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population.
    Stanford RH; Blanchette CM; Roberts MH; Petersen H; Fuhlbrigge AL
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):343-51. PubMed ID: 23083688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies.
    Delea TE; Hagiwara M; Dalal AA; Stanford RH; Blanchette CM
    Curr Med Res Opin; 2009 Jan; 25(1):1-13. PubMed ID: 19210134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
    Delea TE; Hagiwara M; Stanford RH; Stempel DA
    Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.
    Akazawa M; Biddle AK; Stearns SC
    Clin Ther; 2008; 30 Spec No():1003-16. PubMed ID: 18640475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
    Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
    Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population.
    Simoni-Wastila L; Yang HW; Blanchette CM; Zhao L; Qian J; Dalal AA
    Curr Med Res Opin; 2009 Nov; 25(11):2729-35. PubMed ID: 19778165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
    Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
    J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
    Roberts MH; Dalal AA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():221-33. PubMed ID: 22500122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
    Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
    Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.
    Lee TA; Schumock GT; Bartle B; Pickard AS
    Pharmacotherapy; 2009 Sep; 29(9):1039-53. PubMed ID: 19698009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COPD-related healthcare utilization and costs after discharge from a hospitalization or emergency department visit on a regimen of fluticasone propionate-salmeterol combination versus other maintenance therapies.
    Dalal AA; Shah M; D'Souza AO; Mapel DW
    Am J Manag Care; 2011 Mar; 17(3):e55-65. PubMed ID: 21504260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD.
    Dalal AA; Petersen H; Simoni-Wastila L; Blanchette CM
    J Med Econ; 2009; 12(4):339-47. PubMed ID: 19827993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 112.